Tarextumab Biosimilar Monoclonal Antibody (NOTCH2/NOTCH3) for Research
Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-551-1mg | 1mg | 618 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody |
| INN Name | Tarextumab |
| Target | NOTCH2&3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | OncoMed Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Pancreatic cancer;Small cell lung cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | MorphoSys HuCAL Phage Display;XmAb Engineering Technology |

